The major findings were as follows: (1) Serum AnxA1 level was significantly higher in SCAP patients than in non-SCAP patients, particularly in nonsurvivors, but was unrelated to CAP etiology. The gene discussed is ANXA1; the disease is syringocystadenoma papilliferum.